Last reviewed · How we verify
AZD2014
At a glance
| Generic name | AZD2014 |
|---|---|
| Also known as | Vistusertib, Everolimus/Afinitor, vistusertib, AZ12729279 |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer (PHASE1)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (PHASE1)
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (PHASE1)
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (PHASE2)
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |